Amgen and UCB Provide Regulatory Update on Status of EVENITY ™ (romosozumab) in the EU
THOUSAND OAKS, Calif. and BRUSSELS, June 27, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the companies have been informed the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Application for EVENITYTM (romosozumab) for the treatment of severe osteoporosis. The companies intend to submit a written notice for a re-examination by the CHMP.
"After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year,1 and these ...
Source: Amgen News Release - June 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket
Two Biotherapeutic Companies Receive Lab Space and Other Benefits to Further Advance Innovative Science at Bay Area Life Sciences Incubator
SAN FRANCISCO, June 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) today announced that Regencor and Nitrome Biosciences have each been awarded an Amgen Golden Ticket to MBC BioLabs. The companies receive priority admission or renewal for one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen's scientific and business leaders to help advance their scientific programs....
Source: Amgen News Release - June 25, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership
Collaboration Will Apply IPD's de novo Protein Design Expertise to Biotech Drug Discovery
THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the University of Washington's Institute for Protein Design (IPD), which is revolutionizing its field of science by creating custom-designed proteins from scratch to improve human health, today announced a broad collaboration that will cover multiple projects with a goal of testing new technologies and creating protein-building approaches that can be broadly applied to the search for new medicines.
Under the terms of the agreement, Amg...
Source: Amgen News Release - June 19, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces BLINCYTO ® (blinatumomab) Five-Year Overall Survival Data At EHA 2019
Phase 2 Single-Arm BLAST Study Shows Median Overall Survival of 36.5 Months in Patients With Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years
Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data
THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the five-year overall survival (OS) analysis from the single-arm, Phase 2 BLAST study that evaluated BLINCYTO® (blinatumomab) in patients with minimal residual disease (MRD)-positive acute lymphoblastic...
Source: Amgen News Release - June 16, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Amgen And Allergan's KANJINTI ™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)
Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin
Third FDA Approval From Amgen's Biosimilars Portfolio
THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the reference product, Herceptin® (trastuzumab): for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
"The FDA approval...
Source: Amgen News Release - June 13, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution
THOUSAND OAKS, Calif., June 12, 2019 /PRNewswire/ --
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law.
Shareholders in the Un...
Source: Amgen News Release - June 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Intermountain Healthcare and deCODE genetics Launch Groundbreaking DNA Study of 500,000 People to Find New Links Between Genetics and Disease
Study Represents Largest DNA Mapping Effort Undertaken in U.S. from a Single PopulationREYKJAVIK, ICELAND, and SALT LAKE CITY – Intermountain Healthcare and deCODE genetics have announced a major global collaboration and study focused on discovering new connections between genetics and human disease that will involve the collection of half a million DNA samples. The initiative, called the HerediGene: Population Study, represents the largest and most comprehensive DNA mapping effort to date in the United States from a single population. For the study, which is voluntary and ...
Source: Amgen News Release - June 12, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in Rancho Palos Verdes, Calif. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potenti...
Source: Amgen News Release - June 7, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019
AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research
First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors
FDA Grants AMG 510 Orphan Drug Designation for KRASG12C-Positive Non-Small Cell Lung and Colorectal Cancers
THOUSAND OAKS, Calif., June 3, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose ...
Source: Amgen News Release - June 3, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Highlights The Versatility Of The BiTE ® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019
Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO®
Investigational AMG 212 (Pasotuxizumab) Phase 1 Study Explores Use of BiTE Platform in a Solid Tumor
THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating investigational bispecific T cell engager (BiTE®) molecules were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Data presented included updated investigational AMG 420 safety a...
Source: Amgen News Release - June 2, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)
THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's oncology program and data presented at ASCO 2019 including clinical data being presented for the Company's KRAS G12C inhibitor AMG 510 and BiTE® molecules AMG 420 and AMG 212.
Live audio of the investor meeting will be broadcast over th...
Source: Amgen News Release - May 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Additional Irrevocable Undertakings To Accept Amgen's Recommended Public Cash Offer To The Shareholders Of Nuevolution
THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ --
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law.
Shareholders in the U...
Source: Amgen News Release - May 29, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Joins With Community Oncology Networks For New Research Collaboration
Amgen Community Oncology Research Collaborators (ACORC) Will Work to Expand Clinical Trial Access to Cancer Patients Treated Outside of Academic Centers
First Members Include US Oncology Research and TRIO-US With UCLA
THOUSAND OAKS, Calif., May 28, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiative to enhance access by community centers to innovative oncology clinical research. Fewer than one in 20 adult cancer patients in the U.S. have participated in a clinical trial.1 The...
Source: Amgen News Release - May 28, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen announces a recommended public cash offer to the shareholders of Nuevolution
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ --
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law.
Shareholders in the ...
Source: Amgen News Release - May 22, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting.
The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors. Each director received approximately 96 percent or more of the v...
Source: Amgen News Release - May 21, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
